Pharmacopeia Announces Accelrys, a New Leader in Scientific Software

- Accelrys to Represent the Best in Software For

Chemical and Pharmaceutical Research -



Apr 02, 2001, 01:00 ET from Pharmacopeia, Inc.

    PRINCETON, N.J., April 2 /PRNewswire/ -- Pharmacopeia, Inc. (Nasdaq:   PCOP)
 today introduced Accelrys, a new identity for its software subsidiary.
 Accelrys is formed from the combination of four leading specialist companies
 owned by Pharmacopeia -- Molecular Simulations Inc. (MSI), Synopsys Scientific
 Systems, Oxford Molecular, and the Genetics Computer Group (GCG). The 2000 pro
 forma revenues of this business exceeded $90 million. Pharmacopeia's software
 subsidiaries will begin operating as Accelrys on June 1, 2001.
     Pharmacopeia operates two related businesses. Pharmacopeia's Drug
 Discovery business is a leader in experimentation-based technologies and
 services for the pharmaceutical and biotechnology industries.  Accelrys is the
 first company to offer a complete spectrum of integrated scientific software
 and related consulting services to accelerate pharmaceutical discovery and
 chemical development. Pharmacopeia's Chairman, President, and Chief Executive
 Officer, Dr. Joseph A. Mollica, said the debut of Accelrys signals a new era
 for Pharmacopeia, "Our two businesses will continue to work closely together
 to ensure that our software products are optimized to real laboratory
 environments, and that our Drug Discovery business is equipped with the
 state-of-the-art in simulation and informatics."
     Dr. Michael Stapleton, Chief Operating Officer, unveiled the name,
 structure, and objectives of Accelrys at the American Chemical Society (ACS)
 meeting in San Diego. Accelrys is the product of an integration process that
 has combined the organizations, products, technologies, and creative visions
 of its four component companies.
     According to Dr. Stapleton, the result is a new leader in scientific
 software, "Accelrys will provide the pharmaceutical and chemical industries
 with the best science and technology in simulation, bioinformatics,
 cheminformatics, workflow, and decision support.  We gain significant value
 from the interaction and integration of these technologies.  The scale of our
 new operation allows us to invest more effectively in our R&D and to develop
 services to be offered by our new Consulting Group." Accelrys has over
 500 employees located worldwide. Sites include major Centers of Excellence in
 San Diego CA, Princeton NJ, and Cambridge UK, and Technology Centers in Leeds
 UK and Madison WI.
     Dr. Stapleton explained the company's strategy, "We will continue to
 extend our capabilities across a product range encompassing genomics,
 structural biology, and the design and development of drugs, materials, and
 chemical processes.  Across these activities, we will facilitate the creation,
 management, and use of chemical and biological information. We will integrate
 our technologies with each other, with personal productivity tools, and with
 corporate IT infrastructures.  Our vision is of an integrated software
 platform supporting enterprise-wide R&D decisions."
     Accelrys also introduced its new Consulting Services group at the ACS
 Meeting. "This new, highly skilled team is the best way to meet the unique
 needs of our clients," said Robert J. White, Senior Vice President of Sales
 and Consulting Services at Accelrys. "Consulting Services is a great team of
 expert scientists and software engineers who understand customers' businesses
 and research processes, and work with them to develop solutions tailored to
 their requirements and corporate systems."
     Pharmacopeia (http://www.pharmacopeia.com) is a leader in enabling science
 and technology that improves and accelerates drug discovery and chemical
 development. Pharmacopeia's Software segment develops and commercializes gene
 sequence analyses, molecular modeling and simulation, cheminformatics,
 bioinformatics, workflow, and decision support software for the life sciences
 and materials research.  It also provides consulting services to its customers
 in drug discovery and chemical development.  Pharmacopeia's Drug Discovery
 segment integrates proprietary small molecule combinatorial and medicinal
 chemistry, high-throughput screening, in-vitro pharmacology, computational
 methods, and informatics to discover and optimize lead compounds and to
 accelerate customers' drug discovery efforts.  Pharmacopeia employs
 approximately 750 people, generated 2000 revenues of approximately
 $119 million, and is headquartered in Princeton, NJ.
 
     When used anywhere in this document, the words "expects", "believes",
 "anticipates", "estimates" and similar expressions are intended to identify
 forward-looking statements. Pharmacopeia has based these forward-looking
 statements on its current expectations about future events. Such statements
 are subject to risks and uncertainties including, but not limited to, the
 successful implementation of Pharmacopeia's strategic plan, the acceptance of
 new products, the obsolescence of existing products, the resolution of
 existing and potential future patent issues, additional competition, changes
 in economic conditions, and other risks described in documents Pharmacopeia
 has filed with the Securities and Exchange Commission, including its most
 recent report on Form 10-K and subsequent reports on Form 10-Q. All
 forward-looking statements in this document are qualified entirely by the
 cautionary statements included in this document and such filings. These risks
 and uncertainties could cause actual results to differ materially from results
 expressed or implied by forward-looking statements contained in this document.
 These forward-looking statements speak only as of the date of this document.
 Pharmacopeia disclaims any undertaking to publicly update or revise any
 forward-looking statements contained herein to reflect any change in its
 expectations with regard thereto or any change in events, conditions or
 circumstances on which any such statement is based.
 
 

SOURCE Pharmacopeia, Inc.
    PRINCETON, N.J., April 2 /PRNewswire/ -- Pharmacopeia, Inc. (Nasdaq:   PCOP)
 today introduced Accelrys, a new identity for its software subsidiary.
 Accelrys is formed from the combination of four leading specialist companies
 owned by Pharmacopeia -- Molecular Simulations Inc. (MSI), Synopsys Scientific
 Systems, Oxford Molecular, and the Genetics Computer Group (GCG). The 2000 pro
 forma revenues of this business exceeded $90 million. Pharmacopeia's software
 subsidiaries will begin operating as Accelrys on June 1, 2001.
     Pharmacopeia operates two related businesses. Pharmacopeia's Drug
 Discovery business is a leader in experimentation-based technologies and
 services for the pharmaceutical and biotechnology industries.  Accelrys is the
 first company to offer a complete spectrum of integrated scientific software
 and related consulting services to accelerate pharmaceutical discovery and
 chemical development. Pharmacopeia's Chairman, President, and Chief Executive
 Officer, Dr. Joseph A. Mollica, said the debut of Accelrys signals a new era
 for Pharmacopeia, "Our two businesses will continue to work closely together
 to ensure that our software products are optimized to real laboratory
 environments, and that our Drug Discovery business is equipped with the
 state-of-the-art in simulation and informatics."
     Dr. Michael Stapleton, Chief Operating Officer, unveiled the name,
 structure, and objectives of Accelrys at the American Chemical Society (ACS)
 meeting in San Diego. Accelrys is the product of an integration process that
 has combined the organizations, products, technologies, and creative visions
 of its four component companies.
     According to Dr. Stapleton, the result is a new leader in scientific
 software, "Accelrys will provide the pharmaceutical and chemical industries
 with the best science and technology in simulation, bioinformatics,
 cheminformatics, workflow, and decision support.  We gain significant value
 from the interaction and integration of these technologies.  The scale of our
 new operation allows us to invest more effectively in our R&D and to develop
 services to be offered by our new Consulting Group." Accelrys has over
 500 employees located worldwide. Sites include major Centers of Excellence in
 San Diego CA, Princeton NJ, and Cambridge UK, and Technology Centers in Leeds
 UK and Madison WI.
     Dr. Stapleton explained the company's strategy, "We will continue to
 extend our capabilities across a product range encompassing genomics,
 structural biology, and the design and development of drugs, materials, and
 chemical processes.  Across these activities, we will facilitate the creation,
 management, and use of chemical and biological information. We will integrate
 our technologies with each other, with personal productivity tools, and with
 corporate IT infrastructures.  Our vision is of an integrated software
 platform supporting enterprise-wide R&D decisions."
     Accelrys also introduced its new Consulting Services group at the ACS
 Meeting. "This new, highly skilled team is the best way to meet the unique
 needs of our clients," said Robert J. White, Senior Vice President of Sales
 and Consulting Services at Accelrys. "Consulting Services is a great team of
 expert scientists and software engineers who understand customers' businesses
 and research processes, and work with them to develop solutions tailored to
 their requirements and corporate systems."
     Pharmacopeia (http://www.pharmacopeia.com) is a leader in enabling science
 and technology that improves and accelerates drug discovery and chemical
 development. Pharmacopeia's Software segment develops and commercializes gene
 sequence analyses, molecular modeling and simulation, cheminformatics,
 bioinformatics, workflow, and decision support software for the life sciences
 and materials research.  It also provides consulting services to its customers
 in drug discovery and chemical development.  Pharmacopeia's Drug Discovery
 segment integrates proprietary small molecule combinatorial and medicinal
 chemistry, high-throughput screening, in-vitro pharmacology, computational
 methods, and informatics to discover and optimize lead compounds and to
 accelerate customers' drug discovery efforts.  Pharmacopeia employs
 approximately 750 people, generated 2000 revenues of approximately
 $119 million, and is headquartered in Princeton, NJ.
 
     When used anywhere in this document, the words "expects", "believes",
 "anticipates", "estimates" and similar expressions are intended to identify
 forward-looking statements. Pharmacopeia has based these forward-looking
 statements on its current expectations about future events. Such statements
 are subject to risks and uncertainties including, but not limited to, the
 successful implementation of Pharmacopeia's strategic plan, the acceptance of
 new products, the obsolescence of existing products, the resolution of
 existing and potential future patent issues, additional competition, changes
 in economic conditions, and other risks described in documents Pharmacopeia
 has filed with the Securities and Exchange Commission, including its most
 recent report on Form 10-K and subsequent reports on Form 10-Q. All
 forward-looking statements in this document are qualified entirely by the
 cautionary statements included in this document and such filings. These risks
 and uncertainties could cause actual results to differ materially from results
 expressed or implied by forward-looking statements contained in this document.
 These forward-looking statements speak only as of the date of this document.
 Pharmacopeia disclaims any undertaking to publicly update or revise any
 forward-looking statements contained herein to reflect any change in its
 expectations with regard thereto or any change in events, conditions or
 circumstances on which any such statement is based.
 
 SOURCE  Pharmacopeia, Inc.